P/E at 36.84 vs Industry's 36.87: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Near-Industry P/E Reflects Balanced Market View

The current P/E of Sun Pharmaceutical Industries Ltd stands at 36.84, almost identical to the Pharmaceuticals & Biotechnology industry average of 36.87. This near-equal valuation suggests that the market neither applies a significant premium nor a discount to the stock relative to its peers. Such parity often indicates that investors are pricing in the company’s fundamentals and growth prospects in line with sector expectations. However, this equilibrium also means that any deviation in earnings or sector dynamics could quickly shift the stock’s relative attractiveness. Sun Pharmaceutical Industries Ltd’s valuation thus remains finely balanced, reflecting a cautious but steady market stance.

Performance Across Timeframes: Strong Long-Term Gains Tempered by Recent Stability

Examining the stock’s returns reveals a compelling divergence between short- and long-term performance. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a robust 19.53% gain, significantly outperforming the Sensex’s 2.88% decline. This outperformance extends over longer horizons, with three-year returns at 71.23% versus the Sensex’s 19.30%, and five-year returns surging 148.89% compared to the Sensex’s 42.09%. Such figures underscore the company’s sustained growth trajectory and resilience within the Pharmaceuticals & Biotechnology sector.

In contrast, the short-term momentum is more subdued. The stock’s one-month gain of 0.18% slightly trails the Sensex’s 0.46%, while the three-month return of 5.03% marginally outpaces the Sensex’s 4.52%. The one-week and one-day performances are also closely aligned with the broader market, with the stock down 0.53% and 0.07% respectively, compared to the Sensex’s declines of 0.83% and 0.29%. This pattern suggests a period of consolidation or cautious trading after a strong multi-year rally — is this a temporary pause or a sign of shifting investor sentiment? The data indicates that while the stock remains resilient, short-term volatility is more pronounced.

Moving Average Configuration: Mixed Signals Amid Recent Consolidation

The technical picture for Sun Pharmaceutical Industries Ltd reveals a nuanced trend. The stock currently trades above its 50-day, 100-day, and 200-day moving averages, signalling strength over medium to long-term horizons. However, it remains below the 5-day and 20-day moving averages, indicating some short-term weakness or profit-taking pressure. This configuration often points to a recent pullback within a broader uptrend, where the stock is digesting gains before potentially resuming its advance. The 50-day and longer moving averages provide a solid support base, but the short-term averages suggest caution — is this a genuine recovery or a dead-cat bounce? The interplay of these averages will be critical in determining the stock’s near-term trajectory.

Sector Context: Mixed Results Reflect Varied Industry Dynamics

The Pharmaceuticals & Biotechnology sector has seen a mixed bag of results recently. Among 21 stocks that have declared results, 10 reported positive outcomes, 8 were flat, and 3 posted negative results. This distribution highlights a sector grappling with uneven growth drivers and competitive pressures. Sun Pharmaceutical Industries Ltd’s ability to maintain steady gains and a valuation in line with the industry average suggests it is navigating these challenges effectively. However, the sector’s varied performance also means that relative strength will be a key factor for investors to monitor closely.

Rating Context: Previously Rated Hold, Now Reassessed

MarketsMOJO had previously assigned a Hold rating to Sun Pharmaceutical Industries Ltd. The rating was updated on 8 June 2026, reflecting a reassessment of the company’s fundamentals and market position. While the current rating is not disclosed, the data-driven approach behind the change underscores the importance of valuation, performance, and technical factors in the evaluation process. What is the current rating for Sun Pharmaceutical Industries Ltd given these data points? This question remains central for investors seeking clarity amid shifting market conditions.

Conclusion: Data Reflects a Balanced Valuation with Mixed Momentum Signals

The comprehensive data on Sun Pharmaceutical Industries Ltd reveals a stock trading at a valuation almost identical to its industry peers, supported by strong long-term returns and a mixed but generally positive sector backdrop. The short-term performance and moving average configuration suggest a phase of consolidation or cautious trading, with the stock holding key support levels but facing resistance in the near term. The reassessment of the rating from Hold to a new status reflects these nuanced dynamics — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider? The current rating provides the answer.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →